Skip to main content
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. — Investor Relations & Filings

Ticker · SANA ISIN · US7995661045 US Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2023-04-28 Proxy Solicitation & In…
Country US United States of America
Listing US SANA

About Sana Biotechnology, Inc.

https://sana.com/

Sana Biotechnology, Inc. is a company that develops engineered cells as medicines to address the underlying causes of disease. Its core strategy involves two primary platforms: in vivo therapies designed to repair and control genes within a patient's existing cells, and ex vivo therapies that replace missing or damaged cells with new, functional ones. The company utilizes proprietary technologies, such as engineered fusogen proteins, for the targeted delivery of therapeutics. Sana's pipeline is focused on advancing drug candidates for a range of diseases, including diabetes, B-cell cancers, and B-cell related autoimmune disorders.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes information about the Annual Meeting of Stockholders, the date and time, voting instructions, and proposals to elect directors and ratify the appointment of the independent auditor. It does not contain the full proxy statement itself but rather an overview and notice regarding the availability of proxy materials. The document is about soliciting votes and providing information for the meeting, which fits the definition of Proxy Solicitation & Information Statement (PSI). The document length is about 4900 characters, which is consistent with a proxy statement or related materials. Therefore, the correct classification is PSI.
2023-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-28 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-04-26 English
PRIMARY DOCUMENT
Director's Dealing
2023-04-11 English
PRIMARY DOCUMENT
Director's Dealing
2023-04-11 English
8-K - MANAGEMENT CHANGES
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports to announce major events that shareholders should know about. The content specifically details the appointment of a new Executive Vice President and President of Research and Development, as well as the resignation of another executive. This is a clear announcement of changes in the company's senior management. There are no financial statements or detailed financial data present, so it is not an annual or quarterly report. The document is not a proxy statement, earnings release, or any other type of report. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2023-04-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.